[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].

Abstract	To assess the potency, efficacy and toxicity of abacavir/lamivudine (ABC/3TC) versus tenfovir/emcitrabine (TDF/FTC) with efavirenz (EFV) in naive patients with HIV infection a prospective observational study was carried out to evaluate immunovirological parameters every three months and metabolic parameters every six months. In all, 21 patients were enrolled (10 on ABC/3TC and 11 on TDF/FTC). Fisher's test revealed no statistically significant difference between the two arms in terms of immunological recovery and control of viral replication. For metabolic parameters at week 48 no statistically significant differences were noted between the two arms. The two ABC/3TC and TDF/FTC backbones showed the same potency; ABC had a more negative impact on metabolic parameters without statistical power.
Authors	Martina Gottardi, Massimiliano Lanzafame, Emanuela Lattuada, Fabio Soldani, Fabio Boccafoglio, Ercole Concia
Journal	Le infezioni in medicina (Infez Med) Vol. 17 Issue 3 Pg. 151-8 (Sep 2009) ISSN: 1124-9390 [Print] Italy
Vernacular Title	Efficacia e sicurezza dei regimi TAM-sparing in pazienti naïve con infezione da HIV.
PMID	19838086 (Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References	Alkynes Anti-HIV Agents Benzoxazines Cyclopropanes Dideoxynucleosides Organophosphonates Deoxycytidine Lamivudine Tenofovir Emtricitabine Adenine efavirenz Thymidine abacavir
Topics	Adenine (analogs & derivatives) Adult Alkynes Anti-HIV Agents (administration & dosage, adverse effects, therapeutic use) Benzoxazines (pharmacology, therapeutic use) CD4 Lymphocyte Count Cyclopropanes Deoxycytidine (analogs & derivatives) Dideoxynucleosides Drug Therapy, Combination Emtricitabine Female HIV Infections (blood, drug therapy) HIV-1 Humans Hyperinsulinism (chemically induced) Hyperlipidemias (chemically induced) Lamivudine Male Middle Aged Mutation Organophosphonates Prospective Studies Tenofovir Thymidine (metabolism) Treatment Outcome Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!